Sage Therapeutics, Inc. (SAGE) Financials
SAGE Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-03-31 | 767.6 million | 61.8 million |
| 2023-12-31 | 882.3 million | 82.7 million |
| 2023-09-30 | 949.7 million | 133.0 million |
| 2023-06-30 | 1.1 billion | 97.9 million |
SAGE Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-03-31 | -37.8 million | 13.7 million |
| 2023-12-31 | -119.4 million | 12.9 million |
| 2023-09-30 | -136.2 million | 28.7 million |
| 2023-06-30 | -131.6 million | 11.7 million |
SAGE Net Income
No data available :(
SAGE Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-03-31 | 718.3 million | - | 3.3 million |
| 2023-12-31 | 753.2 million | - | 5.2 million |
| 2023-09-30 | 876.1 million | - | 7.0 million |
| 2023-06-30 | 1.0 billion | - | 8.7 million |
SAGE Shares Outstanding
SAGE Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-03-31 | - | 71.7 million | 52.6 million | -597000 |
| 2023-12-31 | 112000 | 64.3 million | 55.1 million | -76000 |
| 2023-09-30 | 328000 | 101.9 million | 78.1 million | - |
| 2023-06-30 | 112000 | 97.2 million | 75.5 million | 76000 |
SAGE Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-03-31 | 7.9 million | 1.3 million |
| 2023-12-31 | 78.0 million | 820000 |
| 2023-09-30 | 2.7 million | 905000 |
| 2023-06-30 | 2.5 million | 205000 |
SAGE
Price: $12.91
52 week price:
Payout Ratio Range:
Earnings Per Share: -8.39 USD
P/E Ratio: -2.11
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 427700
Ebitda: -74.2 millionMarket Capitalization: 838.9 million